Lincosamide monotherapy treatment of methicillin-resistant Staphylococcus aureus pneumonia in tropical Australia: a case series.
Stuart CampbellSimon SmithJosh HansonPublished in: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2024)
Existing recommended first-line antibiotic agents for MRSA pneumonia have several shortcomings. We reviewed 29 cases of community- and hospital-acquired MRSA pneumonia managed at our hospital. Lincosamide monotherapy was administered to 21/29 (72%) and was the predominant antibiotic regimen (> 50% course duration) in 19/29 (66%). Patients receiving lincosamide-predominant monotherapy were no more likely to die or require intensive care unit admission than patients receiving vancomycin-predominant monotherapy (5/19 (26%) versus 4/7 (57%), p = 0.19); 5/7 (71%) patients admitted to ICU and 4/5 (80%) bacteraemic patients received lincosamide-predominant monotherapy. MRSA pneumonia can be safely treated with lincosamide monotherapy if the isolate is susceptible.
Keyphrases
- methicillin resistant staphylococcus aureus
- combination therapy
- staphylococcus aureus
- intensive care unit
- open label
- healthcare
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- mental health
- climate change
- peritoneal dialysis
- randomized controlled trial
- ejection fraction
- community acquired pneumonia
- adverse drug
- smoking cessation
- extracorporeal membrane oxygenation
- replacement therapy
- acute respiratory distress syndrome